Abstract
Background: Asthma exacerbation is an acute or sub-acute episode of progressive worsening of asthma symptoms and can have significant impacts on the daily life of patients. In 2016, 12.4 million current asthmatics (46.9%) in the U.S. had at least one asthma exacerbation in the previous year. Objective: The objectives of this study were to predict the risk of asthma exacerbations and to explore potential risk factors involved in progressive asthma. Methods: We proposed a time-sensitive attentive neural network to predict asthma exacerbation using clinical variables from electronic health records (EHRs). The clinical variables were collected from the Cerner Health Facts database between 1992 and 2015 including 31,433 asthmatic adult patients. Interpretations of both the patient level and the cohort level were investigated based on the model parameters. Results: The proposed model obtains an AUC value of 0.7003 through 5-fold cross-validation, which outperforms the baseline methods. The results also demonstrate that the addition of elapsed time embeddings considerably improves the performance on this dataset. Through further analysis, it was witnessed that risk factors behaved distinctly along the timeline and across patients. We also found supporting evidence from peer-reviewed literature for some possible cohort-level risk factors such as respiratory syndromes and esophageal reflux. Conclusions: The proposed time-sensitive attentive neural network is superior to traditional machine learning methods and performs better than state-of-the-art deep learning methods in realizing effective predictive models for the prediction of asthma exacerbation. We believe that the interpretation and visualization of risk factors can help the clinical community to better understand the underlying mechanisms of the disease progression.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This research was partially supported by the National Library of Medicine of the National Institutes of Health under award number R01LM011829, the National Institute of Allergy and Infectious Diseases of the National Institutes of Health under award number 1R01AI130460, National Center for Advancing Translational Sciences of the National Institutes of Health under award number U01TR02062, and the Cancer Prevention Research Institute of Texas (CPRIT) Training Grant #RP160015.
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The Cerner data used is available for external users if sponsored by UTHealth SBMI faculty, have a UTHealth account, and have signed a Cerner data user agreement that is co-signed by the sponsoring SBMI faculty member.
